Charles Bankhead is a Staff Writer at MedPage Today. He covers a range of topics within medicine and healthcare, focusing on oncology, pancreatic cancer research, radiation oncology, immunotherapy, hematology, and endocrinology, as well as cannabis and psychedelics. His work has been featured in Knowledia, MDEdge, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Charles Bankhead's focus is primarily on medical research, clinical trials, FDA approvals, and scientific developments in healthcare and pharmaceuticals. His coverage includes citing data from various studies and press releases.
If you are reaching out to Charles, consider providing insights or commentary based on recent medical research findings or clinical trial outcomes. Expert opinions related to FDA approvals, drug therapies, or challenges in specific areas of healthcare could be well-received by him.
Since his geographic focus is not specified but his topics are broad and universal, pitches can come from experts across the globe who have valuable insights into these areas of medical research and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Charles Bankhead
Long-term follow-up consistent with earlier report, a hint of benefit in high-grade disease
By: Charles Bankhead
GLP-1 agonists not helpful, may be harmful whereas neural, topical strategies often useful
By: Charles Bankhead
Significantly higher pCR rate, better PFS linked to diet-associated reductions in insulin
By: Charles Bankhead
— News, features, and commentary about cancer-related issues A systematic review of studies of exposure to pollutants at coal mining operations
By: Charles Bankhead
Lack of high-level evidence has hindered treatment development, but some patients do improve
Complete remission rate of 69% in blastic plasmacytoid dendritic cell neoplasm
By: Charles Bankhead
News, features, and commentary about cancer-related issues
By: Charles Bankhead
Prospective clinical trials needed to validate the findings
By: Charles Bankhead
Applies to most patients with one or two positive sentinel lymph nodes
By: Charles Bankhead
— Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations
